On June 12, 2025, Quince Therapeutics, Inc. entered into a Securities Purchase Agreement with institutional investors and certain members of the Company's management. The Company will issue and sell a total of 6,671,928 shares of its common stock and pre-funded warrants to purchase up to 2,000,000 shares of common stock. Additionally, accompanying warrants to purchase up to 8,671,928 shares of common stock will be issued. The total gross proceeds from this private placement are approximately $11.5 million. Each share and accompanying warrant are sold at a combined price of $1.325.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.